Table I.
Patient characteristics
| Patient characteristics | ||||||
|---|---|---|---|---|---|---|
| Total patients, n (%) | 26 (100) | |||||
| Sex, male, n (%) | 11 (42.3) | |||||
| Family history positive for HS, n (%) | 2 (7.7) | |||||
| Smoker, n (%) | 18 (69.2) | |||||
| Age of HS onset, mean ± SD | 22.2 ± 9.7 | |||||
| Age of HS diagnosis, mean ± SD | 35.2 ± 16.1 | |||||
| Body mass index class, kg/m2, median (range) | 34.0 (18.9–55.4) |
|
|
|||
| Anti-IL17 (n) |
Anti-IL23 (n) |
|
||||
| 18.5–24.9 | 3 | 4 | ||||
| 25–29.9 | 3 | 3 | ||||
| 30–34.9 | 5 | 1 | ||||
| 35–39.9 | 5 | 2 | ||||
| Number of prior lines of treatment received, median, range | 3 (1–6) | |||||
| Age at adalimumab start, years, mean ± SD | 36.5 ± 13.8 | |||||
| Use of topical clindamycin concomitant to anti-IL17 or anti-Il23, prn (% patients) |
12 (46.2%) |
|
|
|||
|
|
T0 |
Ts |
T3 |
T6 |
T9 |
T12 |
| Patients on Tx | Anti-IL17 (16) | Anti-IL17 (16) | Anti-IL17 (16) | Anti-IL17 (14) | Anti-IL17 (9) | Anti-IL17 (8) |
| Anti-IL23 (10) | Anti-IL23 (10) | Anti-IL23 (10) | Anti-IL23 (9) | Anti-IL23 (9) | Anti-IL23 (9) | |
| IHS4 score (anti-IL17), mean (± SD) | 22.4 ± 9.9 | 21.1 ± 11.1 | 18.7 ± 9.9 | 17 ± 10.6 | 15.2 ± 10.4 | 14.1 ± 12.4 |
| Median | 20.0 Weeks on Tx (mean ± SD): 70.6 ± 40.4 |
18 | 19 | 16 | 17 | 11 |
| IHS4 score (anti-IL23), mean ± SD | 22 ± 10.8 | 17.1 ± 13.4 | 12.9 ± 12.7 | 8.6 ± 9.2 | 7.1 ± 7.2 | 5.1 ± 6.3 |
| Median | 19.0 Weeks on Tx (mean ± SD): 104.1 ± 53.6 |
17 | 12 | 7 | 6 | 4 |
| p = 0.054 | p = 0.054 | p=0.103 | p = 0.124 | |||
| HiSCR achievement (anti-IL17) | – | Achieved: 1 (6.3%) Not achieved: 15 |
Achieved: 6 (37.5%) Not achieved: 8 |
Achieved: 6 (37.5%) Not achieved: 3 |
Achieved: 5 (31.3%) Not achieved: 3 |
|
| HiSCR achievement (anti-IL23) | – | Achieved: 2 (20%) Not achieved: 8 |
Achieved: 9 (90%) Not achieved: 1 |
Achieved: 9 (90%) Not achieved: 1 |
Achieved: 9 (90%) Not achieved: 1 |
|
| p = 0.259 | p = 0.027 | p = 0.213 | p = 0.163 | |||
| DLQI (anti-IL17), mean (range) | 18.5 (4–28) | 15.4 (4–28) | 14 (2–24) | 12.5 (1–26) | 11.5 (0–26) (p = 0.01) | |
| DLQI (anti-IL23), mean (range) | 16.8 (8–28) | 12.4 (2–24) | 8.2 (0–16) | 6.2 (0–10) | 4.8 (0–10) (p < 0.01) | |
HS: hidradenitis suppurativa; Tx: therapy; SD: standard deviation; IHS4 score: number of nodules multiplied by 1 + number of abscesses multiplied by 2 + number of draining tunnels multiplied by 4. Total score ≤ 3: mild disease, 4–10: moderate disease, 11≥ severe disease; HiSCR: achievement defined as ≥ 50% reduction in inflammatory lesion count and no increase in abscesses or fistulas compared with baseline; T0: time zero, adalimumab first prescription; Ts: time of swap to anti-IL17/anti-IL23 agent; T3: time at 3 months; T6: time at 6 months; T9: time at 9 months; T12: time at 12 months; DLQI: Dermatology Life Quality Index; prn: pro re nata). Statistically significant values are given in bold text.